Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | DNM2 | P50570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28466119 | 0.98 | TLR8 (0.51) | TLR8KMT2AKCNH3TLR7KDM4E | |
| Phosphine SCHEMBL28770506 | 0.98 | TLR8 (0.51) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL4451532 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL754956 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL3297429 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL3296575 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL1034958 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL8752650 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL3301451 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E | |
| SCHEMBL468517 | 0.98 | KMT2A (0.53) | TLR8KMT2AKCNH3TLR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195637-B | Release coating composition and articles made therefrom | 3M创新有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-113195637-B | Release coating composition and articles made therefrom | 3M创新有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-115873403-A | High GWIT halogen-free flame-retardant glass fiber reinforced nylon | 江苏蔚观新材料科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-112409786-B | Low-mold-scale halogen-free flame-retardant thermoplastic polyamide composition and preparation method and application thereof | 金发科技股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| CN-112409786-A | Low-mold-fouling halogen-free flame-retardant thermoplastic polyamide composition and preparation method and application thereof | 金发科技股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| CN-1039757-A | Thin polymer film | ICI PLC (GB) | 1990-02-21 | — | — | CN | disclosed |
| CN-1039555-A | RECEIVER SHEET | ICI PLC (GB) | 1990-02-14 | — | — | CN | disclosed |
| CN-1038617-A | Antiadhesion barrier | ICI PLC (GB) | 1990-01-10 | — | — | CN | disclosed |
| EP-0348062-A1 | Polymeric films | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-12-27 | — | — | EP | disclosed |
| EP-0187458-B1 | POLYMERIC FILMS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-30 | — | — | EP | disclosed |
| US-4728561-A | POLYETHER KETONE AND SULFONATED POLYESTER | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-01 | — | — | US | disclosed |
| US-4704325-A | ALUMINUM ON THERMOPLASTIC SUBSTRATE, PRIMER OF SULFONATED POLYESTER | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-03 | — | — | US | disclosed |
| EP-0191979-A2 | Coated shaped article formed from a polyaryl ether | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-08-27 | — | — | EP | disclosed |
| EP-0187458-A1 | Polymeric films | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-07-16 | — | — | EP | disclosed |
| EP-0185470-A1 | Polymeric films | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | TLR8 2317/4885KMT2A 2239/4885KCNH3 1951/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | TLR8 2317/4885KMT2A 2239/4885KCNH3 1951/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | TLR8 2317/4885KMT2A 2239/4885KCNH3 1951/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | TLR8 2317/4885KMT2A 2239/4885KCNH3 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.